ABBV Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeP/E ratio107.92Forward 15.53
EPS (TTM)$2.05-46.2% YoY
Profit margin5.8%HEALTHCARE
Market cap$390.87BMega cap
Wall Street coverage
$253.55median target· current $172.13 (+47.3%)32 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- 15.53
- PEG ratio
- 0.61
- P/B
- 50.46
- P/S (TTM)
- 6.22
- EV/EBITDA
- 26.85
Profitability & growth
- ROE (TTM)
- 62.3%
- Operating margin
- 32.2%
- Revenue growth YoY
- 12.4%
- Dividend yield
- 3.0%
- Beta
- 0.31
Last earnings
Apr 29, 2026 · Estimate $2.67 · Reported $2.65
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
12 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About AbbVie Inc
Company profileAbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$390.87B
Shares outstanding$1.77B
52W high$239.13
52W low$176.00
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent